Valeo Financial Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Valeo Financial Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3	Closed	–	–	1786
2019 Q4	$0	Buy	+3	New	+$199	﹤0.01%	1623

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Valeo Financial Advisors's ANIP Position: Q1 2020 in Review

Valeo Financial Advisors sold out of ANI Pharmaceuticals (ANIP) in Q1 2020, closing a stake of 3 shares.

Valeo Financial Advisors first reported a position in ANIP in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 140 funds tracked by Wall St. Rank hold ANIP as of Q1 2020.

Valeo Financial Advisors reported no remaining ANI Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Valeo Financial Advisors sold 3 ANI Pharmaceuticals shares in Q1 2020.
Valeo Financial Advisors first reported a position in ANI Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Valeo Financial Advisors's ANI Pharmaceuticals position peaked at $0 in Q4 2019.
140 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2020.

Based on Valeo Financial Advisors's 13F filing for Q1 2020, filed 13 Apr 2020.